帕利哌酮缓释片与喹硫平治疗精神分裂症的对照研究

目的探讨帕利哌酮缓释片治疗精神分裂症的疗效及安全性。方法将67例精神分裂症患者随机分为帕利哌酮组(34例)和喹硫平组(33例),疗程8周,在治疗前及治疗后2,4,6,8周时采用阳性及阴性症状量表(PANSS)、治疗中出现的症状量表(TESS)评定疗效和不良反应。并于治疗前、中、后检测泌乳素水平。结果治疗结束时,帕利哌酮组显效率62%,有效率88%;喹硫平组显效率64%,有效率85%,两组间的疗效差异无显著性(P>0.05)。两组PANSS总分和各因子分均较治疗前明显下降(P<0.01),帕利哌酮组在第二周末的评分明显低于喹硫平组(P<0.05),余时点组间比较差异无显著性(P>0.05)。不良反应总体发生率两组间差异无显著性(P>0.05)。帕利哌酮组催乳素水平明显升高,喹硫平组则无影响,二组间比较有显著性差异(P<0.01)。结论帕利哌酮缓释片对精神分裂症患者的总体疗效与喹硫平相当,但起效更早,且耐受性更高。

Control study of paliperidone extended-Release tablet and quetiapine for Schizophrenic patients

OBJECTIVE To explore the efficacy and safety of paliperidone extended-release tablet for patients with schizophrenia. METHODS 67 patients with schizophrenia were randomly divided into pailperidone group （n = 34） and quetiapine group （n = 33） for an 8-week-study, The curative effects and side effects were assessed with positive and negative syndrome scale （PANSS） and treatment emergent symptom scale （TESS） before treatment, at the ends of the 2, 4, 6 and 8 week after treatment. The prolactin level was detected before, during and after treatment. RESULTS At the end of treatment, the excellence rate and effective rate in pailperidone group were 62 % and 88 %, and those in quetiapine group were 64 % and 85 %, there was no significant difference （P 〉 0.05） .Both the total PANSS scores and sub-scales scores in the two groups lowered obviously compared with before treatment （P 〈 0.01 ）, and significance shown 2 weeks after the treatment between the two groups, but there was no significant difference at the other points （P 〉0.05）. There was no significant difference in the total incidence rate of untoward reaction between the two groups （P 〉0.05）. The prolactin level in pailperidone group heightened obviously, but that in quetiapine group had no changes, there was significant difference between the two groups （P 〈 0.01）. CONCLUSION The medication paliperidone ER has the similary efficacy with the medication of qutiapine, but has earlier efficacy and better tolerance.